Miist Therapeutics, an Alameda CA-based physics-based developer of inhaled medicines, raised $7M in funding.
Backers included Refactor Capital, 1517 Fund, Freeflow Ventures, Entrepreneur First, and California Innovation Fund, amongst others.
The corporate intends to make use of the funds to speed up its two energetic applications in migraine and smoking cessation.
Led by CEO Dalton Signor, Miist Therapeutics applies a physics-based method to develop inhaled therapies which might be sooner appearing and simpler than in the present day’s customary of care. Its core expertise is an inhaler that makes use of ultrasonic vibration to generate and ship 2-micron aqueous drug particles to the peripheral lung, the place they’re immediately absorbed into the bloodstream. Utilizing this novel method, the corporate is growing new inhaled therapies that may ship immediate reduction for a number of the commonest and debilitating situations.
Miist has clinically validated its method and is at the moment advancing two property: MST-01 for the therapy of smoking habit and MST-02 for the therapy of migraine. Part 1 outcomes for MST-01 show the pace of Miist’s therapies, with sufferers reaching 92% symptom reduction in solely 2 minutes publish dosing.
FinSMEs
05/02/2025
